172 related articles for article (PubMed ID: 27513300)
1. The Rho-ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia.
Basbous S; Levescot A; Piccirilli N; Brizard F; Guilhot F; Roy L; Bourmeyster N; Gombert JM; Herbelin A
J Pathol; 2016 Nov; 240(3):262-268. PubMed ID: 27513300
[TBL] [Abstract][Full Text] [Related]
2. The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells.
Burthem J; Rees-Unwin K; Mottram R; Adams J; Lucas GS; Spooncer E; Whetton AD
Leukemia; 2007 Aug; 21(8):1708-14. PubMed ID: 17554385
[TBL] [Abstract][Full Text] [Related]
3. Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients.
Rossignol A; Levescot A; Jacomet F; Robin A; Basbous S; Giraud C; Roy L; Guilhot F; Turhan AG; Barra A; Herbelin A; Gombert JM
Eur J Immunol; 2012 Jul; 42(7):1870-5. PubMed ID: 22585600
[TBL] [Abstract][Full Text] [Related]
4. Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.
Inselmann S; Wang Y; Saussele S; Fritz L; Schütz C; Huber M; Liebler S; Ernst T; Cai D; Botschek S; Brendel C; Calogero RA; Pavlinic D; Benes V; Liu ET; Neubauer A; Hochhaus A; Burchert A
Cancer Res; 2018 Nov; 78(21):6223-6234. PubMed ID: 30166420
[TBL] [Abstract][Full Text] [Related]
5. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
6. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
8. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
10. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
Elgehama A; Chen W; Pang J; Mi S; Li J; Guo W; Wang X; Gao J; Yu B; Shen Y; Xu Q
Cancer Lett; 2016 Mar; 372(1):82-8. PubMed ID: 26721204
[TBL] [Abstract][Full Text] [Related]
11. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
[TBL] [Abstract][Full Text] [Related]
13. Inverse relationship between myeloid maturation and leukotriene C4 synthase expression in normal and leukemic myelopoiesis-consistent overexpression of the enzyme in myeloid cells from patients with chronic myeloid leukemia.
Tornhamre S; Stenke L; Granzelius A; Sjölinder M; Näsman-Glaser B; Roos C; Widell S; Lindgren JA
Exp Hematol; 2003 Feb; 31(2):122-30. PubMed ID: 12591277
[TBL] [Abstract][Full Text] [Related]
14. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
Terme M; Borg C; Guilhot F; Masurier C; Flament C; Wagner EF; Caillat-Zucman S; Bernheim A; Turhan AG; Caignard A; Zitvogel L
Cancer Res; 2005 Jul; 65(14):6409-17. PubMed ID: 16024645
[TBL] [Abstract][Full Text] [Related]
15. Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib.
Clapp GD; Lepoutre T; El Cheikh R; Bernard S; Ruby J; Labussière-Wallet H; Nicolini FE; Levy D
Cancer Res; 2015 Oct; 75(19):4053-62. PubMed ID: 26359456
[TBL] [Abstract][Full Text] [Related]
16. Bcr-Abl tyrosine kinase inhibitors: a patent review.
Desogus A; Schenone S; Brullo C; Tintori C; Musumeci F
Expert Opin Ther Pat; 2015 Apr; 25(4):397-412. PubMed ID: 25656651
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Roy M; Sarkar R; Mukherjee A; Mukherjee S
Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
[TBL] [Abstract][Full Text] [Related]
18. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
19. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]